BACKGROUND In an earlier study, intravenous (i.v.) ibandronate 6 mg administered every 3-4 weeks had a similarly good renal safety profile whether infused over 15 or 60 min in women with breast cancer and bone metastases. This current study focuses on the renal safety of the extended use of ibandronate. PATIENTS AND METHODS Patients completing the original study could choose to enter a follow...

A close look at the writings of the Middle Eastern and North African scholars who lived in the Middle Ages (roughly between A.D. 476-1500) reveals an immense body of theoretical knowledge pertaining to the humanities, and behavioral and social sciences. A partial list of the scholars who wrote on these issues includes names such as Abu Yusuf (8th century), Abul-Fadl Al-Dimishgi (9th century), A...

PURPOSE Bone metastasis invariably increases morbidity and mortality. This study compares the effects of ibandronate and paclitaxel on bone structure and its mechanical properties and biochemical turnover in resorption markers using an immunocompetent Walker 256-Sprague-Dawley model, which was subjected to tumor-induced osteolysis. MATERIALS AND METHODS Seventy rats were divided equally into ...

Data from two open-label trials (PRIOR and CURRENT) of women with postmenopausal osteoporosis or osteopenia were evaluated to assess whether monthly oral and quarterly intravenous (IV) ibandronate dosing improved self-reported gastrointestinal (GI) tolerability for patients who had previously experienced GI irritation with bisphosphonate (BP) use. In PRIOR, women who had discontinued daily or w...

For defining the optimal regimen of a treatment of osteoporosis with an intravenous bisphosphonate one needs to know the duration of action of a single dose of the given drug. This allows us to establish the frequency by which a given dose has to be administered for obtaining a sufficient suppression of bone resorption over a longer period. In this study 1 and 2 mg Ibandronate were given as a s...

Hanae Harchaoui, Bousayna Iraqi, Houria knouni, Youness Taboz, Hasnae Benkirane, Hassan Aguenaou, Amina Barkat Equipe de recherche en santé et nutrition du couple mère enfant, faculté de médecine et de pharmacie de Rabat, université Mohamed VRABAT, Service de médecine et réanimation néonatales, Centre Hospitalier Ibn Sina, Rabat, Maroc 2 Université Ibn Tofail, Unité Mixte. Corresponding author:...

Background: CDSO is a condition affecting predominantly the mandible and long bones of young females, characterised by episodes of intractable pain on a background of chronic discomfort. The aetiology is unknown, but the bone sclerosis is associated with abnormal osteoblast and osteoclast function. Methods: We report 3 cases in which symptoms and biochemical markers responded to treatment with ...

Stroke or cerebrovascular accident (CVA) is caused by a disturbance of the blood supply to the brain and an accruing loss of brain function. The first recorded observations were in 2455 BC and it has been studied intensely by ancient physicians throughout history. In the early medieval period, Ibn Sina (980-1025 AD) called stroke sekteh and described it extensively. Some of Ibn Sina's definitio...

Ibn Sina (980-1037 AD), known by his full name Abu Ali al-Hussain ibn Abdallah ibn Sina and the Latin name 'Avicenna', was a Persian scholar who is primarily remembered for his contributions to the science of medicine. He authored Al-Qanun fi al-Tibb (The Canon of Medicine). Sections of his work are devoted to detailed descriptions of a number of infectious illnesses, particularly rabies. Avice...

Ibn Sina is generally known as one of the most important philosophers and physicians, one whose contributions to science and philosophy have attracted numerous studies. This article provides an outline of his philosophy of science which determined the framework for his understanding of natural philosophy. Rather than being of historical interest, the article argues, Ibn Sina's philosophy of sci...